Katherine Lu is a Partner at LYZZ Capital. She has over ten years of equity research and investment experience in global healthcare sectors. Previously, Ms. Lu worked at Sectoral Asset Management, responsible for its emerging market healthcare investment. Prior to that, Ms. Lu served as a Managing Director at Cowen & Co, heading its China Healthcare equity research. Previously, Ms. Lu was a Managing Director and Head of China Equity Research at Oppenheimer & Co. In addition, she also worked as a Director at CIBC World Market, covering US Specialty Pharma. Ms. Lu started her Wall Street career as an associate analyst at SG Cowen, covering US Large-Cap Medtech. Prior to Wall Street, Ms. Lu worked as a drug discovery scientist at Johnson & Johnson and Roche for six years, focusing on cancer therapeutics. She also worked as a healthcare management consultant at Bogart Delafield Ferrier. Ms. Lu holds a BS in chemistry from Nanjing University, an MS in organic chemistry from Iowa State University and an MBA
from New York University Stern School of Business. Ms. Lu is also a CFA charterholder.